Healthcare
Auxly Cannabis Group Inc.(CBWTF)
Live Price
Offline$0.124
+2.48% today
1Y Change
+125.00%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $190.00M
- Revenue Growth
- +23.7%
- EPS Growth
- +330.9%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Auxly Cannabis Group Inc. (CBWTF) is a Healthcare stock with a market cap of $190.00M and listed on OTC. The stock last traded around $0.12 and up 125.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +23.7%, EPS growth of +330.9%, a dividend yield of 0.0%. What stands out right now is revenue +23.7%, EPS +330.9%, free cash flow +66.6% with operating margin 21.6% and ROIC 13.9%. Valuation is more restrained than many high-expectation growth names at P/E 4.4 and price/sales 1.3. Stock Foundry combines CBWTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+23.7% vs +7.6% peer median
Operating Margin
Above sector median
+21.6% vs +19.4% peer median
P/E
Below sector median
4.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 15, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +23.7% and EPS at +330.9%, with operating margin around 21.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | โ | -5.9% | +2.0% | +9.8% |
2026 Mar 26, 2026 | โ | +3.2% | -2.1% | +10.5% |
2025 Nov 13, 2025 | โ | -5.1% | -12.0% | -4.3% |
Benchmark Edge
CBWTF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CBWTF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CBWTF Max Drawdown
-35.88%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CBWTF and SPY.
Company Overview
Auxly Cannabis Group Inc.
OTC
Auxly Cannabis Group Inc. is a prominent entity in the legal cannabis industry, focusing on the cultivation, production, and distribution of cannabis products. Headquartered in Canada, Auxly engages in a vertically integrated business model encompassing product innovation, branding, and retail partnerships. The company's primary function is to deliver diverse, high-quality cannabis offerings, including recreational and medicinal cannabis, through an extensive network of subsidiaries and partners across Canada and internationally. By investing in cultivation facilities and strategic partnerships, Auxly aims to ensure efficient operations and a robust supply chain. The company is instrumental in shaping the evolving legal cannabis landscape, introducing new product formats and innovative consumer experiences. Auxly's reach in the market includes contributions to legal cannabis research, compliance with regulatory standards, and collaborations with health and wellness sectors, positioning it as a key player in the pharmaceutical and nutraceutical segments of the industry. Its role in the market signifies Auxly's commitment to growth and sustainability in the burgeoning cannabis economy.
- Leadership
- Mr. Hugo M. Alves
- Employees
- 388
- Street Address
- 777 Richmond Street West, Unit 002
- Mailing
- Toronto, ON, M6J 0C2
- Region
- Toronto, ON, Canada
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 4.4
- EV/EBITDA
- 4.3
- Price/Sales
- 1.3
- Price/Book
- 1.0
Growth
- Revenue
- +23.7%
- EPS
- +330.9%
- Free Cash Flow
- +66.6%
Profitability
- Gross Margin
- 57.3%
- Operating Margin
- 21.6%
- Net Margin
- 27.6%
- ROE
- 27.2%
- ROIC
- 13.9%
Balance Sheet
- Debt/Equity
- 0.32
- Current Ratio
- 2.20
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.